Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in Silico/in Vitro work flow

Irene Kouskoumvekaki; Rasmus Koefoed Petersen; Filip Filipov Fratev; Olivier Taboureau; Thomas Eiland Nielsen; Tudor Oprea; Si Brask Sonne; Esben N. Flindt; Svava Osk Jonsdottir; Karsten Kristiansen

doi:10.1021/ci3006148

Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in Silico/in Vitro work flow

Irene Kouskoumvekaki, Rasmus Koefoed Petersen, Filip Filipov Fratev, Olivier Taboureau, Thomas Eiland Nielsen, Tudor Oprea, Si Brask Sonne, Esben N. Flindt, Svava Osk Jonsdottir, Karsten Kristiansen

25 Citationer (Scopus)

Abstract

Full agonists to the peroxisome proliferator-activated receptor (PPAR)γ, such as Rosiglitazone, have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity. Nevertheless, PPARγ is involved in the expression of genes that control glucose and lipid metabolism and is an important target for drugs against type 2 diabetes, dyslipidemia, atherosclerosis, and cardiovascular disease. In an effort to identify novel PPARγ ligands with an improved pharmacological profile, emphasis has shifted to selective ligands with partial agonist binding properties. Toward this end we applied an integrated in silico/in vitro workflow, based on pharmacophore- and structure-based virtual screening of the ZINC library, coupled with competitive binding and transactivation assays, and adipocyte differentiation and gene expression studies. Hit compound 9 was identified as the most potent ligand (IC50 = 0.3 μM) and a relatively poor inducer of adipocyte differentiation. The binding mode of compound 9 was confirmed by molecular dynamics simulation, and the calculated free energy of binding was -8.4 kcal/mol. A novel functional group, the carbonitrile group, was identified to be a key substituent in the ligand-protein interactions. Further studies on the transcriptional regulation properties of compound 9 revealed a gene regulatory profile that was to a large extent unique, however functionally closer to that of a partial agonist.

Originalsprog	Engelsk
Tidsskrift	Journal of Chemical Information and Modeling
Vol/bind	53
Udgave nummer	4
Sider (fra-til)	923-937
Antal sider	15
ISSN	1549-9596
DOI	https://doi.org/10.1021/ci3006148
Status	Udgivet - 22 apr. 2013

Adgang til dokumentet

10.1021/ci3006148

http://dx.doi.org/10.1021/ci3006148

Citationsformater

Kouskoumvekaki, I., Petersen, R. K., Fratev, F. F., Taboureau, O., Nielsen, T. E., Oprea, T., Sonne, S. B., Flindt, E. N., Jonsdottir, S. O., & Kristiansen, K. (2013). Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in Silico/in Vitro work flow. Journal of Chemical Information and Modeling, 53(4), 923-937. https://doi.org/10.1021/ci3006148

Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in Silico/in Vitro work flow. / Kouskoumvekaki, Irene; Petersen, Rasmus Koefoed; Fratev, Filip Filipov et al.

I: Journal of Chemical Information and Modeling, Bind 53, Nr. 4, 22.04.2013, s. 923-937.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Kouskoumvekaki, I, Petersen, RK, Fratev, FF, Taboureau, O, Nielsen, TE, Oprea, T, Sonne, SB, Flindt, EN, Jonsdottir, SO & Kristiansen, K 2013, 'Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in Silico/in Vitro work flow', Journal of Chemical Information and Modeling, bind 53, nr. 4, s. 923-937. https://doi.org/10.1021/ci3006148

@article{3145df536e554d1ca3e8f23c523da135,

title = "Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in Silico/in Vitro work flow",

abstract = "Full agonists to the peroxisome proliferator-activated receptor (PPAR)γ, such as Rosiglitazone, have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity. Nevertheless, PPARγ is involved in the expression of genes that control glucose and lipid metabolism and is an important target for drugs against type 2 diabetes, dyslipidemia, atherosclerosis, and cardiovascular disease. In an effort to identify novel PPARγ ligands with an improved pharmacological profile, emphasis has shifted to selective ligands with partial agonist binding properties. Toward this end we applied an integrated in silico/in vitro workflow, based on pharmacophore- and structure-based virtual screening of the ZINC library, coupled with competitive binding and transactivation assays, and adipocyte differentiation and gene expression studies. Hit compound 9 was identified as the most potent ligand (IC50 = 0.3 μM) and a relatively poor inducer of adipocyte differentiation. The binding mode of compound 9 was confirmed by molecular dynamics simulation, and the calculated free energy of binding was -8.4 kcal/mol. A novel functional group, the carbonitrile group, was identified to be a key substituent in the ligand-protein interactions. Further studies on the transcriptional regulation properties of compound 9 revealed a gene regulatory profile that was to a large extent unique, however functionally closer to that of a partial agonist.",

author = "Irene Kouskoumvekaki and Petersen, {Rasmus Koefoed} and Fratev, {Filip Filipov} and Olivier Taboureau and Nielsen, {Thomas Eiland} and Tudor Oprea and Sonne, {Si Brask} and Flindt, {Esben N.} and Jonsdottir, {Svava Osk} and Karsten Kristiansen",

year = "2013",

month = apr,

day = "22",

doi = "10.1021/ci3006148",

language = "English",

volume = "53",

pages = "923--937",

journal = "Journal of Chemical Information and Modeling",

issn = "1549-9596",

publisher = "American Chemical Society",

number = "4",

}

TY - JOUR

T1 - Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in Silico/in Vitro work flow

AU - Kouskoumvekaki, Irene

AU - Petersen, Rasmus Koefoed

AU - Fratev, Filip Filipov

AU - Taboureau, Olivier

AU - Nielsen, Thomas Eiland

AU - Oprea, Tudor

AU - Sonne, Si Brask

AU - Flindt, Esben N.

AU - Jonsdottir, Svava Osk

AU - Kristiansen, Karsten

PY - 2013/4/22

Y1 - 2013/4/22

N2 - Full agonists to the peroxisome proliferator-activated receptor (PPAR)γ, such as Rosiglitazone, have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity. Nevertheless, PPARγ is involved in the expression of genes that control glucose and lipid metabolism and is an important target for drugs against type 2 diabetes, dyslipidemia, atherosclerosis, and cardiovascular disease. In an effort to identify novel PPARγ ligands with an improved pharmacological profile, emphasis has shifted to selective ligands with partial agonist binding properties. Toward this end we applied an integrated in silico/in vitro workflow, based on pharmacophore- and structure-based virtual screening of the ZINC library, coupled with competitive binding and transactivation assays, and adipocyte differentiation and gene expression studies. Hit compound 9 was identified as the most potent ligand (IC50 = 0.3 μM) and a relatively poor inducer of adipocyte differentiation. The binding mode of compound 9 was confirmed by molecular dynamics simulation, and the calculated free energy of binding was -8.4 kcal/mol. A novel functional group, the carbonitrile group, was identified to be a key substituent in the ligand-protein interactions. Further studies on the transcriptional regulation properties of compound 9 revealed a gene regulatory profile that was to a large extent unique, however functionally closer to that of a partial agonist.

AB - Full agonists to the peroxisome proliferator-activated receptor (PPAR)γ, such as Rosiglitazone, have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity. Nevertheless, PPARγ is involved in the expression of genes that control glucose and lipid metabolism and is an important target for drugs against type 2 diabetes, dyslipidemia, atherosclerosis, and cardiovascular disease. In an effort to identify novel PPARγ ligands with an improved pharmacological profile, emphasis has shifted to selective ligands with partial agonist binding properties. Toward this end we applied an integrated in silico/in vitro workflow, based on pharmacophore- and structure-based virtual screening of the ZINC library, coupled with competitive binding and transactivation assays, and adipocyte differentiation and gene expression studies. Hit compound 9 was identified as the most potent ligand (IC50 = 0.3 μM) and a relatively poor inducer of adipocyte differentiation. The binding mode of compound 9 was confirmed by molecular dynamics simulation, and the calculated free energy of binding was -8.4 kcal/mol. A novel functional group, the carbonitrile group, was identified to be a key substituent in the ligand-protein interactions. Further studies on the transcriptional regulation properties of compound 9 revealed a gene regulatory profile that was to a large extent unique, however functionally closer to that of a partial agonist.

U2 - 10.1021/ci3006148

DO - 10.1021/ci3006148

M3 - Journal article

C2 - 23432662

SN - 1549-9596

VL - 53

SP - 923

EP - 937

JO - Journal of Chemical Information and Modeling

JF - Journal of Chemical Information and Modeling

IS - 4

ER -